Copyright ©The Author(s) 2019.
World J Gastroenterol. Aug 28, 2019; 25(32): 4614-4628
Published online Aug 28, 2019. doi: 10.3748/wjg.v25.i32.4614
Table 1 Codified locoregional treatments: Indications, advantages and disadvantages
Ablation (RFA)BCLC-A patientsCurativeLow complication rates rates in HCC > 3 cm
New devices (MWA, Cryoablation, HIFU, Laser, IRE)Relatively unfeasible in “complex” sites/lesions
TACEBCLC-B patients without PVTSuper-selective deliveryPalliative
Great variety of materialsHeterogeneous population
No standardization
Combined therapy (RFA + TACE)Selected BCLC-A/B patientsComplimentary and synergistic effectNo standardization
Better than RFA and TACE alone
SIRTSelected BCLC-B/C patients not amenable for TACE or SorafenibSuper-selective deliveryHigh costs